13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Page 28 of 68

Page 28 of 68 – SEC Filing

(h)
The FSSP VI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, certain of the Ordinary Shares held by Ute as reported herein. The Farallon Individual Reporting Persons are managers of the FSSP VI General Partner.
(i)
Not applicable.
The Farallon General Partner
(a),(b)
The information set forth in Rows 7 through 13 of the cover page hereto for the Farallon General Partner is incorporated herein by reference.
(c)
None.
(d)
The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, certain of the Ordinary Shares held by the Farallon SPVs as reported herein.  The Farallon Individual Reporting Persons are managing members of the Farallon General Partner.
(e)
Not applicable.
The NSSP General Partner
(a),(b)
The information set forth in Rows 7 through 13 of the cover page hereto for the NSSP General Partner is incorporated herein by reference.
(c)
None.
(d)
The NSSP General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, certain of the Ordinary Shares held by Akubra as reported herein. The Management Company is the manager of the NSSP General Partner.
(e)
Not applicable.
The Management Company
(a),(b)
The information set forth in Rows 7 through 13 of the cover page hereto for the Management Company is incorporated herein by reference.
(c)
None
(d)
The Management Company has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of,

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Page 28 of 68